A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck - NCT01059643-19106(Clinical Trial 665172)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Philadelphia |
|
State:
|
|
PA |
| Zip Code: |
|
19106 |
| Conditions: |
|
Ovarian Cancer - Non Small Cell Lung Cancer - Prostate Cancer - Colorectal Cancer - Gastric Cancer - Esophageal Cancer - Cancer of Head and Neck |
| Purpose: |
|
The purpose of the study is to estimate the rate of response for patients with ovarian,
non-small cell lung, prostate, colorectal, gastroesophageal, and head and neck cancers who
are administered LY2523355.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- diagnosis of ovarian, non-small cell lung, prostate, colorectal, gastroesophageal
cancer, or squamous cell cancer of the head and neck
- Have measurable disease defined by Response Evaluation Criteria in Solid Tumors
(RECIST) 1.1 guidelines (except prostate cancer patients)
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Are willing to follow study procedures for the duration of the study
- Are willing to use an approved contraceptive method during treatment and for 3 months
after discontinuation of study treatment
Exclusion Criteria:
- Have a serious preexisting medical condition that would preclude participation in the
study
- Are pregnant or lactating
- Have received treatment within 28 days of first dose of LY2523355 with a drug that
has not received regulatory approval for any indication
- Have symptomatic, untreated, or uncontrolled central nervous system (CNS) metastases
- Have a second active primary malignancy or a history of a second malignancy requiring
cytotoxic therapy
- Have QTc interval >470 msec or intraventricular conduction delay (IVCD) with QRS >120
msec on screening electrocardiogram (ECG)
- Have active symptomatic fungal, bacterial, and/or known viral infection including
active human immunodeficiency virus (HIV) or viral (A, B, C) hepatitis |
|
|
|
|
|
|
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
January 6, 2011 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|